Daniel McNamara Joins T1D Fund as Head of Strategy to Boost Investment in Type 1 Diabetes Innovation
On May 13, 2025, the T1D Fund announced the appointment of Daniel McNamara as the Head of Strategy and Industry Engagement. This role is pivotal for the fund, aimed at propelling its mission of driving innovation in treatments and potential cures for Type 1 Diabetes (T1D).
The T1D Fund, a dedicated impact investment group, focuses on developing life-changing solutions to treat, prevent, and ultimately cure T1D. McNamara, with a robust background in business strategy and operations, specifically from his tenure at Bristol Myers Squibb (BMS), is expected to leverage his extensive experience to strengthen the Fund's relationships with investors and the scientific community.
Daniel McNamara isn’t a newcomer to strategic leadership. With over 15 years in the industry, he's played a crucial role at BMS, where he led initiatives that resulted in over $100 billion in mergers and acquisition activities. His insights in corporate strategy and experience in navigating complex networks make him uniquely qualified for the new position.
According to Elizabeth Mily, CEO of the T1D Fund, “Dan's deep strategic experience within life sciences will be an important addition as we advance this next chapter.” McNamara will bring renewed focus to the Fund’s efforts in increasing awareness of the challenges still present in current T1D treatment paradigms and will aim to draw greater attention and resources to the space.
In his new role, McNamara will establish the T1D Fund as a central hub for innovation related to T1D. He plans to synthesize information on breakthroughs, emerging scientific insights, and clinical advancements, ensuring that key findings and opportunities are readily available to stakeholders, including investors and industry leaders. His approach will not only strengthen the Fund’s internal strategy but will also create meaningful collaboration opportunities within the broader T1D ecosystem.
McNamara expressed his honor at joining the T1D Fund at such a crucial juncture in the quest for a cure. He emphasized the organization's dynamic approach in combining focused insight on T1D with strong partnerships to facilitate disruptive advancements in therapy. He is eager to work alongside both the investment team and scientific partners to expedite the discovery of effective treatments and potentially transformative therapies.
The T1D Fund operates in collaboration with various venture capitalists, biopharmaceutical companies, and substantial philanthropic organizations, including the Breakthrough T1D initiative and the Helmsley Charitable Trust. Their synergistic efforts strive to fill critical gaps in early-stage developments, fostering breakthroughs in T1D treatment.
As McNamara steps into this critical leadership role, the T1D Fund is poised to increase its impact significantly on Type 1 Diabetes research and treatment initiatives. They aim not merely to serve as investors but as influential thought partners in the biomedical landscape, encouraging innovators to prioritize T1D in their objectives and accelerating the progression from research to tangible therapeutic solutions.
To learn more about the T1D Fund and its mission, visit their website at t1dfund.org or follow them on LinkedIn. Through these initiatives and the newly appointed leadership, the T1D Fund strives to catalyze a new era of investment in T1D that will ultimately lead to significant advancements in the treatment and prospects of living with this chronic condition.
The T1D Fund, a dedicated impact investment group, focuses on developing life-changing solutions to treat, prevent, and ultimately cure T1D. McNamara, with a robust background in business strategy and operations, specifically from his tenure at Bristol Myers Squibb (BMS), is expected to leverage his extensive experience to strengthen the Fund's relationships with investors and the scientific community.
Daniel McNamara isn’t a newcomer to strategic leadership. With over 15 years in the industry, he's played a crucial role at BMS, where he led initiatives that resulted in over $100 billion in mergers and acquisition activities. His insights in corporate strategy and experience in navigating complex networks make him uniquely qualified for the new position.
According to Elizabeth Mily, CEO of the T1D Fund, “Dan's deep strategic experience within life sciences will be an important addition as we advance this next chapter.” McNamara will bring renewed focus to the Fund’s efforts in increasing awareness of the challenges still present in current T1D treatment paradigms and will aim to draw greater attention and resources to the space.
In his new role, McNamara will establish the T1D Fund as a central hub for innovation related to T1D. He plans to synthesize information on breakthroughs, emerging scientific insights, and clinical advancements, ensuring that key findings and opportunities are readily available to stakeholders, including investors and industry leaders. His approach will not only strengthen the Fund’s internal strategy but will also create meaningful collaboration opportunities within the broader T1D ecosystem.
McNamara expressed his honor at joining the T1D Fund at such a crucial juncture in the quest for a cure. He emphasized the organization's dynamic approach in combining focused insight on T1D with strong partnerships to facilitate disruptive advancements in therapy. He is eager to work alongside both the investment team and scientific partners to expedite the discovery of effective treatments and potentially transformative therapies.
The T1D Fund operates in collaboration with various venture capitalists, biopharmaceutical companies, and substantial philanthropic organizations, including the Breakthrough T1D initiative and the Helmsley Charitable Trust. Their synergistic efforts strive to fill critical gaps in early-stage developments, fostering breakthroughs in T1D treatment.
As McNamara steps into this critical leadership role, the T1D Fund is poised to increase its impact significantly on Type 1 Diabetes research and treatment initiatives. They aim not merely to serve as investors but as influential thought partners in the biomedical landscape, encouraging innovators to prioritize T1D in their objectives and accelerating the progression from research to tangible therapeutic solutions.
To learn more about the T1D Fund and its mission, visit their website at t1dfund.org or follow them on LinkedIn. Through these initiatives and the newly appointed leadership, the T1D Fund strives to catalyze a new era of investment in T1D that will ultimately lead to significant advancements in the treatment and prospects of living with this chronic condition.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.